Acquired resistance to therapy is perhaps the greatest challenge to effective clinical management of cancer. With several inhibitors of the mitotic checkpoint kinase MPS1 in preclinical development, we sought to investigate how resistance against these inhibitors may arise so that mitigation or bypass strategies could be addressed as early as possible. Toward this end, we modeled acquired resistance to the MPS1 inhibitors AZ3146, NMS-P715, and CCT251455, identifying five point mutations in the kinase domain of MPS1 that confer resistance against multiple inhibitors. Structural studies showed how the MPS1 mutants conferred resistance by causing steric hindrance to inhibitor binding. Notably, we show that these mutations occur in nontreated cancer cell lines and primary tumor specimens, and that they also preexist in normal lymphoblast and breast tissues. In a parallel piece of work, we also show that the EGFR p.T790M mutation, the most common mutation conferring resistance to the EGFR inhibitor gefitinib, also preexists in cancer cells and normal tissue. Our results therefore suggest that mutations conferring resistance to targeted therapy occur naturally in normal and malignant cells and these mutations do not arise as a result of the increased mutagenic plasticity of cancer cells. Cancer Res; 75(16); 3340-54. Ó2015 AACR.
Introduction
In order for eukaryotic cells to undergo repetitive cell cycles, it is essential that a cell faithfully duplicates and then equally segregates their genome. The regulation of mitosis is achieved through an evolutionary conserved mechanism termed the spindle assembly checkpoint (SAC); an inhibitory signal that prevents metaphase to anaphase transition until all sister chromatid pairs are attached to mitotic spindle (via kinetochores; KT), in a bipolar orientation (1) . MPS1 (monopolar spindle 1; also known as TTK) is a dual specificity serine, threonine, and tyrosine kinase (2) , which is vital for the recruitment of SAC proteins to unattached KTs, the formation of the mitotic checkpoint complex and therefore, the inhibition of the anaphase-promoting complex/cyclosome (APC/C). Furthermore, MPS1 is also required for chromosome alignment and error correction (3) (4) (5) . Thus, following the inhibition of MPS1 kinase activity, cells prematurely exit mitosis with mis-attached/unaligned chromosomes, which causes severe chromosome mis-segregation, aneuploidy, and cell death (6) (7) (8) (9) (10) .
MPS1 has been suggested to be dysregulated in cancer cells; specifically, MPS1 mRNA expression is elevated in a number of cancers relative to normal tissue, including thyroid, breast, lung, bladder, and glioblastoma, higher levels correlating with a higher histologic grade, aggressiveness, and poor patient survival in breast cancer, glioblastoma, and pancreatic ductal adenocarcinoma (11) (12) (13) (14) (15) (16) (17) . Furthermore, breast cancer cell lines deficient in the tumor-suppressor protein PTEN have been reported to be more sensitive to MPS1 depletion or kinase inhibition (18) . As a result, MPS1 has attracted considerable attention as a potential drug target for anticancer therapy, with a number of small-molecule inhibitors recently identified and under development (6) (7) (8) (9) (10) 19) , or entering the clinic (BAY-1161909; clinical trial ID NCT02138812).
The development of acquired resistance is one of the greatest challenges to the effectiveness of targeted therapies in the clinic. A number of different resistant mechanisms have been described, including the upregulation/switching to alternative signaling pathways, drug-efflux pumps, and drug-resistant mutations (20, 21) . One notable example of acquired resistance is from the use of the BCR-ABL1 inhibitor imatinib in the treatment of chronic myeloid leukemia (CML). Resistance to imatinib most commonly occurs through mutations in the BCR-ABL1 kinase domain; the most frequent mutation being the highly resistant gatekeeper mutation p.T315I (22) (23) (24) . Although second-generation inhibitors (dasatinib and nilotinib) are active against many drug-resistant mutations, the p.T315I mutation still confers strong resistance against both drugs (25) (26) (27) . Thus, treating T315I-containing CML remains a significant unmet clinical need, being addressed by third-generation of BCR-ABL1 inhibitors (28, 29) . Encouragingly, pronatinib, designed specifically to overcome p.T315I-induced resistance, has shown efficacy against all BCR-ABL1 mutants tested (30, 31) . However, these discoveries have taken over 10 years; thus, preemptively discovering inhibitors to target resistant mutations may have an important impact on overall patient survival.
Because several MPS1 inhibitors are currently undergoing preclinical and clinical development, we decided to elucidate the potential mechanisms that could render cells resistant to the MPS1 inhibitors AZ3146 and NMS-P715, two of the first MPS1-specific inhibitors to be reported, and our own recently identified inhibitor CCT251455 (6, 7, 19) .
Materials and Methods
Cell culture and molecular cell biology All cells were obtained from the ATCC (LGC Promochem) and cultured in DMEM, 10% fetal calf serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. DLD1 Flp-In T-Rex cells were obtained from S. Taylor (The University of Manchester, Manchester, United Kingdom) and stably transfected as previously described (32) . Cell viability assays were analyzed using CellTiter-Glo Luminescent Cell Viability Assay after 4 days (Promega). Colony formation assays were analyzed using Sulforhodamine B colorimetric assay after 14 days (SRB; Sigma). mRNA was extracted from using the RNeasy Mini Kit (Qiagen) and MPS1 cDNA amplified using ImProm-II Reverse Transcription protocol (Promega). Site-directed mutagenesis was performed using QuickChange II (Agilent Technologies). Tetracycline (Sigma) was used at a final concentration of 1 mg/mL, nocodazole (Sigma) at 200 ng/mL, paclitaxel (Sigma) at 200 nmol/L, and MG132 (Sigma) at 20 mmol/L.
IP-kinase assays
Myc-tagged MPS1 constructs were transfected into HEK293T cells, arrested in nocodazole, lysed in lysis buffer (Cell Signaling Technology) and Myc-MPS1 captured using 7 mg of anti-myc antibody (4A6: Millipore, 05-724) coupled to Protein G Dynabeads (Life Technologies). The immunoprecipitation (IP) was then incubated with 10 mg of myelin basic protein (MBP; Sigma), 166 mmol/L ATP (Sigma) and 5 mCi ATP [g-33P] (PerkinElmer) for 30 minutes at 30 C. Reactions were stopped with SDS loading buffer and boiling at 100 C for 5 minutes, run on NuPAGE TrisAcetate gels (Life Technologies) and stained with SimplyBlue Safestain (Life Technologies). Radioactivity was quantified using a 9410 Typhoon phosphorimager and ImageQuant software (Amersham Biosciences).
Immunofluorescence and time-lapse microscopy
For immunofluorescence, cells were fixed in 1% formaldehyde for 5 minutes at room temperature, quenched in glycine, washed in PBS-Triton X-100 (0.1% PBS-T) and incubated for 1 hour in primary antibodies in PBS-T: MAD2 (Bethyl Laboratories Inc., A300-301A), CDC20 (Millipore, MAB3775), MPS1 (Millipore, 05-682), MPS1 pT33pS37 (Life Technologies, 44-1325G), and ACA (ImmunoVision, HST-0100). After PBS-T washes, cells were incubated with fluorescent-conjugated secondary antibodies (Life Technologies), stained with DAPI (Life Technologies), and mounted onto slides with Vectashield (Vector Labs). Images were acquired using a Zeiss LSM 710 confocal microscope and processed using Velocity 3D Image analysis software (PerkinElmer). Time-lapse microscopy was performed in 96-well Ibidi plate (Thistle Scientific) using a Diaphot inverted microscope (Nikon), in a humidified CO 2 chamber at 37 C, using a motorized stage (Prior Scientific), controlled by Simple PCI software (Compix).
Flow cytometry
Cells were fixed in 70% ethanol, washed in PBS, incubated in 10 mg/mL propidium iodide and 0.5% RNase (Sigma) for 30 minutes and analyzed using LSRII flow cytometer (BD Biosciences). To stain for mitosis, cells were incubated for 1 hour at 4 C with anti-MPM2 antibodies (Millipore, 05-368), then 1 hour at 4 C with FITC-conjugated secondary antibodies (Life Technologies).
Meso scale discovery assay
Cellular IC 50 values for MPS1 pS33pT37 autophosphorylation inhibition were measured as previously described [Naud and colleagues (19) ].
Droplet digital PCR
Droplet digital PCR was carried out using a QX100 Droplet Digital PCR System (Bio-Rad) and TaqMan MGB primer-probes (Applied Biosystems; Supplementary Experimental Procedures). DNA was extracted from cell lines using Puregene cell and tissue kit (Qaigen). Tumor and lymphoblast samples were fresh frozen. An emulsion was made containing 10-mL Supermix buffer (BioRad), 1 mL of primer-probes mix (Life Technologies), DNA and droplet oil using the QX100 droplet-generator (Bio-Rad). PCR reactions were then carried out on a thermal cycler at 95 C for 10 minutes, 40 cycles of 95 C for 15 seconds and 57.5 C to 63.5 C for 1 minute, then 10 minutes at 98 C. Plates were analyzed on a Bio-Rad QX100 droplet reader using QuantaSoft software. Fraction abundances (FA%) were calculated as [a/(aþb)] Â 100, where a is the total number of mutant-positive droplets and b is the total number of wild-type (WT) positive droplets.
Protein production and purification and crystal structure determination
The MPS1-KD WT and mutant proteins were produced as previously described (19, 33) . All crystallization experiments were performed at 18 C by the sitting drop vapor diffusion technique. Soaks were also carried out at 18 C. For cocrystallization experiments, preincubations of protein with ligands were performed for 30 minutes on ice prior to setting up crystallization plates. See Supplementary Experimental Procedures for individual conditions.
Results

The generation of AZ3146-resistant cell lines
To investigate the mechanism through which human cancer cells could develop resistance against MPS1 inhibitors, HCT116 cells were cultured for 10 days in 0.8 mmol/L (the GI 50 ) of the MPS1 inhibitor AZ3146 (7), then 2 mmol/L AZ3146 for 3 weeks. Sixteen clones were isolated and cell lines generated, named AzR1-16, all of which were resistant to AZ3146-induced cell death in cell viability assays (Fig. 1A and B and Supplementary Table S1); AzR3 and 4 had a GI 50 of approximately 3 mmol/L (4-fold resistance), while the remaining clones had a GI 50 of approximately 9 mmol/L (11-fold resistance; Fig. 1A ). Because MPS1 is essential for the (Fig. 1C) ; AzR3 and -4 contained a p.I531M mutation (c.1593A>G), while all the other clones possessed a p.S611G mutation (c.1831A>G; Supplementary Table S1 ). Because all clones containing the same mutation had a similar fold-resistance to AZ3146, we selected one cell line containing each mutation to further characterize their SAC. When we analyzed their cell-cycle profiles by flow cytometry, while in the parental cell line, the G 1 and G 2 -M peaks are increasingly abolished following treatment with 1 and 2 mmol/L AZ3146 (Fig.  1D ), AzR1 and AzR3 remained unaffected, consistent with a functional SAC in the presence of the inhibitor. Likewise, when analyzing mitosis by time-lapse microscopy ( Fig. 1E) , while 2 mmol/L AZ3146 caused the parental cell line to rapidly exited mitosis in 10 minutes, AzR1 and -3 remained in mitosis for the normal length of time ($25 minutes), with no apparent mitotic defects, confirming a functional SAC.
Having created cell lines resistant to AZ3146 (an 8-oxopurine), we subsequently investigated whether these cells are resistant to number of different structural classes of MPS1 inhibitors; a diaminopyridine (ONCOII), triaminopyridine (SNG12), and a pyrazoloquinazoline (NMS-P715), suggesting whether the mutations could cause cross-resistance in the clinic (Fig. 1F ). Using a cell viability assay, we show that the p.I531M-containing AzR3 cell clone was also resistant to the OncoTherapy compound II (ONCOII, patent WO2011016472A1) and NMS-P715 (6) although no resistance was seen to the Shionogi compound 12 (SNG12; ref. 34 ). The p.S611G-containing AzR1 cells conferred up to 10-fold resistance against the ONCOII and SNG12 inhibitors; however, it showed no resistance against NMS-P715. These data suggest that the p.I531M and p.S611G mutations are able to confer resistance against a number of structurally different MPS1 inhibitors that bind to the hinge region of MPS1 kinase domain.
To confirm that these MPS1 mutations alone were sufficient to cause resistance to MPS1 inhibitors, we ectopically expressed the p.I531M, p.S611G, and a double mutant (Dbl) in DLD1 Flp-In TRex cells ( Supplementary Fig. S1A and S1B). Viability assays confirmed that expression of all three mutants, but not WT MPS1, conferred resistance to AZ3146, with the Dbl construct being most effective (Fig. 1G) . Importantly, this drug resistance was also associated with the rescue of SAC override ( Supplementary Fig.  S1C -S1E). Expression of p.I531M, but not p.S611G, could also rescue cell survival following NMS-P715 treatment (Supplementary Fig. S1F ). Thus, these data confirm that expression of drugresistant mutants alone confer resistance to MPS1 inhibitors while not adversely affect mitosis.
To determine the effect of the mutations on MPS1 kinase activity, we performed IP-kinase assays of Myc-tagged constructs. All three mutants phosphorylated themselves and MBP to near WT levels, suggesting they have normal activity (Fig. 1H ). In addition, we measured the inhibition of their kinase activity using an in-cell, fluorescence-based kinase assay using meso scale discovery (MSD) electrochemilluminescence technology (19) , quantifying MPS1 T33/S37 autophosphorylation as a marker for kinase activity. The WT construct had an IC 50 of 1.48 mmol/L, the p.I531M had 3.4 mmol/L, the p.S611G had 19.2 mmol/L, while the double mutant had an IC 50 > 25 mmol/L (Fig. 1I ). MPS1 phosphorylation was further confirmed by immunoblotting ( Supplementary Fig. S1G and S1H). We also generated recombinant full-length MPS1 p.S611G, which was 40-, and 15-fold more resistant to ONCOII and AZ3146 than WT recombinant protein, while NMS-P715 was equipotent (Supplementary Table S2 ). These data confirm that the mutations prevent the inhibition of MPS1 by the small-molecule inhibitor AZ3146.
The generation of NMS-P715-resistant cell lines
Having created cell lines resistant to AZ3146, we subsequently investigated whether different mutations would emerge using a structurally different chemical class. Therefore, we generated HCT116 clones resistant to NMS-P715, the only MPS1 inhibitor tested unaffected by the p.S611G mutation. Table S3 ). One clone contained the previously characterized p.I531M mutation. All cell lines were resistant to NMS-P715-induced cell killing in cell viability assays, conferring a similar fold resistance (Fig. 2B and C and Supplementary Table S3 ). However, this loss of cell viability at 2 mmol/L NMS-P715 was not accompanied by the typical loss of cell-cycle profile associated with MPS1 inhibition (Fig. 2D ), suggesting NMS-P715 caused cell death in an off-target manner. To verify that the cell lines contained a function SAC, the mitosis of the HCT116 cell lines were analyzed by time-lapse microscopy ( Fig. 2E ). Upon treatment with 1 mmol/L NMS-P715, only the parental HCT116 cells rapidly exited mitosis, suggesting that the p.M600T, p.Y568C, and p.C604W mutations prevent SAC override induced by NMS-P715.
Overexpression of p.M600T, p.Y568C, or p.C604W mutant constructs in DLD1 Flp-In T-Rex cells (Supplementary Fig. S2A and S2B) showed that each mutant was sufficient to confer resistance to NMS-P715 (Fig. 2F ), restore the cell-cycle profiles and prevent SAC-override caused by NMS-P715 ( Supplementary  Fig. S2C-S2E ). IP-kinase assays demonstrated that p.Y568C and 0.8 cancerres.aacrjournals.org Downloaded from p.C604W mutants phosphorylated themselves and MBP to WT levels, whereas the p.M600T mutant was only autophosphorylated to 20% of WT levels (Fig. 2G ). Despite this, the p.M600T mutant still robustly phosphorylated MBP to 92% of WT levels. Significantly, all MPS1 mutants were phosphorylated to the same extent in cells during mitosis, confirming that they are all comparably active (Supplementary Fig. 2F ). In MSD assays, all three mutants were resistant to NMS-P175, having an IC 50 of: 3.5 mmol/L (4-fold), 8.2 mmol/L (10-fold), and >16 mmol/L (>21-fold) for the p.M600T, p.Y568C, and p.C604W mutants, compared with approximately 0.77 mmol/L for the WT (Fig. 2H) . In addition, the p.I531M, but not p.S611G, also conferred resistance in the MSD assay (Fig. 2H) . We also demonstrated that p. M600T, p.Y568C, and p.C604W mutants could confer resistance against AZ3146, ONCOII, and SNG12 (Fig. 2I) . Furthermore, a recombinant full-length MPS1 p.C604W mutant conferred 15-fold resistance to AZ3146, 75-fold resistance to ONCOII and 148-fold resistance to NMS-P715, compared with the WT protein (Supplementary Table S2 ). These data together suggest that these mutations are sufficient to cause resistance to MPS1 inhibitors and NMS-P715 causes cell death through additional off-target effects at higher concentrations.
CCT251455: a potent and selective MPS1 inhibitor that overcomes resistance caused by the p.Y568C mutation
We have recently reported the discovery of a potent and selective MPS1 inhibitor CCT251455 (a pyrrolopyridine) with a GI 50 of 0.16 mmol/L in HCT116 cells ( Fig. 3A; ref. 19 ). Using the MSD assay to measure MPS1 autophosphorylation at T676 and T33/S37, MPS1 kinase activity was inhibited at 0.22 and 0.04 mmol/L respectively, consistent with the cell viability data (Fig. 3B) . To confirm that CCT251455 induces phenotypes associated with MPS1 inhibition, we showed that the cell-cycle profiles of HCT116 cells were abolished following 24-hour treatment with 0.32 mmol/L CCT251455 (Fig. 3C) . Likewise, HeLa cells rapidly exited mitosis upon CCT251455 treatment, 98% of which had unaligned chromosomes (Fig. 3D) and CCT251455 rapidly abrogated a previously established Taxol or nocodazole-induced SAC (Fig. 3E) . CCT251455 also severely inhibited the kinetochore recruitment of MAD2, MAD1, ZW10 CDC20, while BUB1 and BUBR1 were reduced ( Fig. 3F and Supplementary Fig. S3 ), consistent with previous reports (7, 35) . Conversely, MPS1 kinetochore localization increased in the presence of CCT251455, although the pT33/S37 and pT676 signals were no longer visible, confirming that inactive MPS1 binds to the kinetochore (7, 36) . As controls, the kinetochore localization of ZWINT-1, CENP-E, CENP-F, and CENP-A pS7 (a marker of Aurora B activity) remained unaffected by inhibitor treatment (Supplementary Fig. S3 ).
To demonstrate whether CCT251455-induced cell death is specifically through MPS1 inhibition, we tested CCT251455 in our five drug-resistant HCT116 cell lines (Fig. 3G) . Both the p.S611G (AzR1) and p.C604W mutant cells (NvR12) conferred high resistance (10-and 8-fold), p.I531M (AzR3) approximately 5-fold, while the p.M600T mutant (NvR1) conferred only 2-fold resistance. However, the p.Y568C mutation (NvR11) did not confer any resistance to CCT251455. This was further confirmed using the MSD assay (Fig. 3H) and in vitro using recombinant p.S611G and p.C604W MPS1 proteins (Supplementary Table S2 ). Interestingly, when we generated drug-resistant HCT116 cell clones against CCT251455 using the same protocol as for AZ3146 and NMS-P715, we identified the p.S611G mutation in all clones, conferring a similar 10-fold resistance to the inhibitor (Supplementary Fig. S4) . These data together demonstrate that CCT251455 kills cells specifically through MPS1 inhibition.
Crystal structures of MPS1 p.S611G in complex with MPS1 inhibitors
To provide insight into the structural basis for the observed resistance of MPS1 to the inhibitors, we introduced the p.S611G mutation into an MPS1 kinase domain construct (MPS1-KD, residues 519-808) used for crystallization experiments (19) and solved the crystal structures of the native (Supplementary Fig. S5 ) and p.S611G MPS1-KD enzyme in binary complexes with the 8-oxopurine (AZ3146), the diaminopyridine (ONCOII), and the pyrrolopyridine compound 1, a close structural analogue of CCT251455.
To our surprise, the binding of AZ3146 to the WT and p.S611G mutant MPS1-KD enzymes is almost identical (Fig. 4A ). AZ3146 binds with two hydrogen bonds to the hinge, one between the purine N1 and Gly605NH atoms, the other between the anilino NH and Gly605O atoms (Fig. 4A) . The N7-methyl group of AZ3146 packs against the gatekeeper Met602 residue, and the N9-cyclopentyl group projects into the space occupied by the NBoc substituent of CCT251455 bound to MPS1. The 2-methoxyanilino moiety projects toward solvent, positioning the piperidine group above the helix-capping Asp608-Ser611 motif (Fig.  4A) . The activation loop was not resolved in either of these structures, most likely due to the use of PEG300 in the crystallization conditions, as noted previously (19) .
The diaminopyridine (ONCOII) also bound in a very similar manner to the native and mutant enzymes in the crystal structures (Fig. 4B) , comparable with the related diaminopyridine inhibitor reported in PDB entry 3VQU. In these crystal structures, the main chain peptide of the gatekeeperþ2 residue, Cys604, is flipped relative to other inhibitor-bound MPS1KD structures, and provides the hinge-binding hydrogen bond interaction between the Cys604 carbonyl with the anilino NH of the inhibitor (Fig. 4B) . The anilino substituent of ONCOII overlays well with the benzamide of the diaminopyridine inhibitor in 3VQU, but projects further toward Ser611, to a similar extent as the methylimidazole group of CCT251455. The 3-methoxynitrile aniline substituent occupies the selectivity pocket next to the side chains of Cys604 and Gln541 and above the post-hinge residues 605-607, also exploited by other MPS1 inhibitors (6, 19) . The pyridine-5-cyano group that points toward the Lys553NZ atom does not appear to be a productive interaction. In the WT ONCOII-MPS1-KD structure, we also observed the almost complete ordering of the activation loop, similar to that observed for a pyrimidodiazipine inhibitor (9), but this was less well-ordered for the p.S611G MPS1-KD bound to ONCOII with a short ordered segment (residues 671-674) contacting the cyclohexyl group of ONCOII, and residues 669-682 not visible in the electron density. However, this is most likely due to the use of PEG300 in crystallization conditions (19) . Likewise, the structure of p.S611G MPS1-KD in a complex with compound 1 (Fig. 4C ) revealed a binding mode nearly identical to the previously reported WT MPS1-KD (PDB 4C4H; ref. 19 ) and very similar to CCT251455. In summary, the crystal structures of both WT and p.S611G MPS1-KD bound to three different classes of MPS1 inhibitors show only minor differences in inhibitor binding mode between the WT and p.S611G mutant proteins. However, importantly, in all three ligand-bound p.S611G MPS1-KD structures, the p.S611G mutation was clearly apparent from the electron density surrounding this residue. Notably, this mutation removes the helix-capping interaction of the Ser side chain with Asp608, and the main chain of the resulting Gly residue is also more flexible; it is therefore likely that the S611G mutation results in greater flexibility of the aD helix. In support of this hypothesis, NMS-P715 is the only inhibitor we have tested with a potency not affected by the S611G mutation and that has a binding mode that is incompatible with the ordering of the activation loop. Therefore, we propose that the conformation of the activation loop residues, which may be affected by the p.S611G mutation, plays an important role in inhibitor resistance.
p.I531M and p.C604W mutations obstruct MPS1 inhibitorbinding Molecular modeling of the p.I531M mutation using the crystal structure of MPS1-KD in complex with ATP (PDB code 3HMN) shows that the p.I531M mutation would not be expected to abrogate MPS1 kinase activity, as a small subset of the commonly observed rotamers of the larger methionine side-chain can still be accommodated next to the bound nucleotide (Fig. 5A) . However, modeling the p.I531M mutation in the MPS1-KD structure bound to AZ3146 shows that all methionine rotamers would clash with the anilino moiety or the cyclopentyl group of the inhibitor (Fig.  5B) . Therefore, it is likely that the I531M mutation would confer resistance to any inhibitor containing both a large group equivalent to the anilino moiety and a substituent similar to the cyclopentyl group of AZ3146. This hypothesis is supported by the fact that the only inhibitor against which the p.I531M mutation in cells did not confer resistance is the recently reported triaminopyridine inhibitor (SNG12; Fig. 1F ), which contains a smaller aniline substituent compared with the other tested MPS1 inhibitors.
In addition to the p.S611G MPS1-KD, we were also able to elucidate the crystal structures of the p.C604W MPS1-KD mutant in complex with the pyrazoloquinazoline NMS-P715. The p.C604W mutation was clearly observed in the electron density after molecular replacement, indicating that the Trp side chain is well ordered in this structure. In comparison with the crystal structure of WT MPS1 bound to NMS-P715 (PDB code 2Â9E), the carbonyl group of Gly605 is rotated toward the ligand, due to steric hindrance by the bulky Trp604 side-chain of the mutant protein (Fig. 5C) . In both the WT and p.C604W mutant structures, the ligand makes two Hbonds to the hinge and an additional H-bond between Lys553 and an amide oxygen atom. The latter H-bond acts as the anchor point for rotation of the ligand away from the hinge region in the C604W MPS1 mutant compared with the WT enzyme. This rotation is caused by the bulky Trp604 side chain, which would otherwise sterically clash with the trifluoromethoxy group of the ligand. All of the other inhibitors used in this study contain a substitution comparable with the anilino 2-trifluoromethoxy group of NMS-P715, explaining the resistance conferred by the p.C604W mutation to all of the MPS1 inhibitors described so far. For ONCOII, the Trp mutation has a dual effect through causing both steric hindrance, as well as by losing a hinge binding interaction with the anilino NH of the inhibitor. 
Discovery of MPS1 inhibitors overcoming MPS1-resistant mutants
Because the p.C604W mutation caused resistance to all the MPS1 inhibitors tested, we set out to design a compound to specifically overcome this mutation. Thus, we synthesized two related pyrrolopyridines in which the chlorine atom was replaced with hydrogen or fluorine (compound 2 and 3; Fig. 6A ). When tested in the drug-resistant cell lines, both compounds were more potent toward NvR12 than the parental HCT116 cells, particularly compound 2, which was 5-fold more potent in cells (Fig. 6B ) and in vitro (Supplementary Table S2 ). However, the other drugresistant mutations still conferred resistance to the inhibitors, with p.S611G giving over 5-fold resistance, while p.Y568C, p.M600T, and p.I531M were limited to approximately 2-fold (Fig. 6B) . We further confirmed this increased effectiveness against p.C604W by flow cytometry; compound 2 caused a loss of cellcycle profiles at 100 nmol/L for NvR12, compared with 600 nmol/L for the parental and >900 nmol/L for AzR1 cells (Fig. 6C) .
To understand why compound 2 was more active against the p.C604W mutation, we determined the structures of both WT and p.C604W MPS1-KD proteins with compound 2 ( Fig. 6D and E). The binding of compound 2 is almost identical to CCT251455, with only a small difference in the torsion angles between aniline and imidazole rings of approximately 14 , due to the smaller H atom in the 2-position of the aniline of compound 2. In the compound 2-bound p.C604W-mutant structure, the P-loop residues from Ser526 to Ser537 are located further away from the kinase hinge than in the WT structure due to the larger Trp604 side chain. This results in a larger hydrophobic surface defined by the side chains of Trp604 and Ile531, against which the aromatic anilino substituent packs. Furthermore, as observed in the p.C604W structure with NMS-P715, due to the larger side chain of Trp604, the carbonyl group of Gly605 is rotated toward the anilino NH of the inhibitor. An important difference between the structures of MPS1 with NMS-P715 and compound 2 is the lack of a 2-anilino substituent in the latter, meaning that compound 2 is not rotated away from the hinge by steric hindrance of the Trp604 side chain. Indeed, the H-bond distance between the anilino NH and the carbonyl oxygen atom of Gly605 is less than 2.8 Å in the p.C604W-mutant structure compared with the equivalent distance of more than 3.2 Å in the WT structure. Therefore, the greater potency of compound 2 versus p.C604W-mutant MPS1 relative to WT is most likely due to a combination of improved hinge-binding and more optimal hydrophobic interactions.
Drug-resistant mutations are preexisting in HCT116 cells
Having discovered a number of mutations that confer drug resistance against multiple MPS1 inhibitors, we aimed to determine whether these mutations are preexisting within the cancer cell population. To this end, we optimized small-nucleotide polymorphism (SNP) assays using the QX100 Droplet Digital PCR System (ddPCR; Bio-Rad) and TaqMan primer probes. An emulsion was made containing approximately 10,000 gDNAcontaining droplets, then following a PCR reaction, the fluorescence of each individual droplet was determined, allowing quantification of the WT and mutant alleles. In each drug-resistant HCT116 cell line, 43% to 50% of the droplets were positive for the mutant allele, confirming the cells were heterozygous for the mutation (Fig. 7A and B) . In parental HCT116 gDNA, the p.S611G mutation was the most frequent mutation found at 0.94%, followed by p.Y568C at 0.3%, while the p.I531M and p.C604W mutations were the least frequent at 0.02% and 0.07% (Fig. 7C) . The number of mutant-positive droplets increased proportionately with increasing concentrations of gDNA and decreased with dilution, suggesting that these mutant-positive droplets are a "true" signal ( Supplementary Fig. S6A and S6B) . Furthermore, the FA of all mutants, except p.Y568C, increased between 10-and 50-fold in HCT116 cells after 3 days selection with 0.8 mmol/L AZ3146 (Supplementary Fig. S6C ).
To address how specific these mutations were, we designed primer probes for p.S611C and p.S611R mutations (A>T and A>C mutations, respectively), and Tyr568 mutated to a stop codon. When we tested HCT116 cells for these alternative mutations, we did not detect a single droplet positive for any of the mutations (Fig. 7D) , whereas 16% to 37.4% of the droplets were positive when spiked with mutant vector. Taken together, these data suggest that the drug-resistant mutations are specific and preexisting within the HCT116 population and not due errors in the technique. In fact, we have seen that within 24 days outgrowth from a single cell, the drug-resistant mutations are detected in HCT116 cells (Supplementary Fig. S6D ). Conversely, using the p.S611G-continaing AzR1 cells, the Gly611 allele is mutated back to Ser in up to approximately 50% of the cells (Supplementary Fig. S6E ), suggesting these bases may be frequently mutated. In addition, these mutations did not appear to give a fitness/growth advantage compared with WT cells when cultured in a 1:1 ratio under normal or low serum conditions (Supplementary Fig. S6F ).
Drug-resistant mutations can be detected in both cancer cells and nontransformed cells
Because HCT116 cells contain a mismatch repair defect, we hypothesized that the FA of the mutations may be higher in this cell line compared with other cancer cells, thus we analyzed a panel of 17 breast and pancreatic cancer cell lines. However, the drug-resistant mutations were typically identified in every cell line at strikingly similar levels (Supplementary Table S4 ), suggesting that these mutations are present in all cancer-cell lines at similar frequencies. In agreement with these data, when we created drugresistant cell lines against AZ3146 and NMS-P715 in CAL51 cells, the two mutations identified were p.S611G for AZ3146-treated cells and p.Y568C for NMS-P715-treated cells ( Supplementary  Fig. S7A and S7B) .
Next, we investigated whether these mutations are found preexisting in patient tumor samples, suggesting they could be selected for in the clinic. We analyzed the gDNA of 14 treatment-na€ ve (BamHI-digested), invasive breast carcinomas of no special type (Supplementary Tables S5 and S6 ; ref. 37). The p.S611G and p.Y568C mutations were detected in every tumor sample, although typically at a lower FA than in the cell lines; <0.2% and <0.09%, respectively (Supplementary Table S5 ). The p.I531M mutation was detected in 13 tumors at 0.1% to 0.4%, the p.C604W in 10 tumors at 0.03% to 0.37%, while the p.M600T was only detected in five samples. The mutations could also be detected in undigested tumor gDNA (Supplementary Table S7) , although in fewer samples and at a lower FA, likely due to a reduced efficiency in the PCR amplification.
To determine whether these preexisting mutations were specific to cancer cells, we then also analyzed eight lymphoblast gDNA samples from healthy individuals. Surprisingly, each mutation was also identified in the majority of lymphoblast samples tested (Supplementary Table S8 ), again with the p.S611G mutation typically at the highest FA. We then also analyzed five normal breast tissue samples for the presence of the p.S611G mutation. p.S611G was identified with a FA of 0.04% to 0.07% in four of the five samples ( Supplementary Fig. S6G ), again suggesting that this mutation is preexisting in normal, nontransformed cells. Finally, to address whether mutations in other genes that confer acquired drug resistance are also naturally occurring, we optimized a SNP assay to identify the EGFR p.T790M gatekeeper mutation, a major cause of resistance to gefitinib treatment. When we analyzed the HCT116 gDNA alone, the p.T790M mutation was detected at a FA of 0.08%, which increased to 99.5% of droplets when spiked with synthetic Ultramer oligos (Fig. 7E) . Furthermore, the p.T790M mutant was detected 12 of the 17 breast and pancreatic cancer cell lines tested, at <0.08% (Supplementary  Table S9A ), in half the lymphoblast samples (Supplementary  Table S9B ), as well as in four of normal breast tissue samples ( Supplementary Fig. S6G ). These results would suggest that point mutations conferring acquired drug resistance to MPS1 and EGFR inhibitors are naturally occurring mutations, preexisting in both normal and cancer cells. 
Discussion
Although kinase inhibitors can be very effective in the clinic (38) , their success has been limited by the emergence of drug resistance. The most common and well-documented causes of drug resistance are mutations or amplifications of the drug target itself, or in alternative genes that activate parallel or downstream signaling pathways (20, 21) . Here, we describe the development of drug-resistant HCT116 cell lines, using the MPS1 inhibitors AZ3146, NMS-P715, and CCT251455. Cell culture models have been used previously to successfully identify mechanisms of resistance that also develop in the clinic (39, 40) . Each inhibitor resulted in the generation of common and drug-specific MPS1 point mutations, with each mutation conferring resistance against multiple MPS1 inhibitors, the effectiveness depending on the binding mode of the inhibitor. Although we identified five mutations contained within the ATP-binding pocket of MPS1, this neither excludes the possibility that other resistant mechanisms may exist, such as drug efflux pumps, nor that additional MPS1 mutations may also cause resistance. For example, BCR-ABL1 tolerates mutations in over 60 amino acid positions that confer drug resistance (24) . Furthermore, ectopic expression of an MPS1 gatekeeper mutant (p.M602Q), can confer resistance to alternative MPS1 inhibitors (9) .
In this article, we extensively characterize novel MPS1 mutations, both in function and their frequency in the population, presenting compelling evidence to explain why specific mutations consistently arise following inhibitor treatment. Using ddPCR, we show that each point mutation is preexisting within every cancer cell line examined at similar frequencies, regardless of their mutational background. Crucially, when we looked for three alternative point mutations, none were detected in the cell population, suggesting that these mutations either do not occur, thus are specific in nature, or they may render MPS1 nonfunctional, thus are eliminated from the population. We also found that multiple inhibitors led to the selection of the most frequent and resistant p.S611G mutation, suggesting that important factors pertinent to the selection of a particular mutation including (i) the fold resistance the mutation confers, as well as (ii) its FA in the population. Interestingly, when looking at the Cosmic or cBioPortal databases, a large number of mutations have been reported in the MPS1 gene in tumor samples, including p.G534E, p. D566G, Y599C, p.M600I, p.V601I, and p.C604F; residues very close to, or the same as we found mutated in this study (p.I531M, p.Y568C, p.M600T, p.C604W, and p.S611G). Although all these previously identified mutations are completely uncharacterized with no functional data reported, and in some cases are unverified, together with our data it suggests that the kinase domain of MPS1 may be frequently mutated in cancer cells, thus providing the potential for cells to develop acquired resistance against inhibitors. However, how frequently these other mutations are found in tumors or are preexisting in normal tissue, whether they affect the function of MPS1, or whether they could confer resistance to MPS1 inhibitors is unknown. Preexisting mutations being specific in nature would also explain why, despite the introduction of gatekeeper mutations into the BRAF V600E protein conferring drug resistance in vitro (41), these mutations have never been identified in cell lines or tissue samples. Thus, we speculate that these mutations are not naturally occurring in BRAF, or are much less frequent compared with other resistant mechanisms (42, 43) .
A critical question for anticancer therapy is what is the origin/ cause of acquired resistance. Our data indicate that acquired drug resistance occurs through the selection of preexisting genetic differences within the tumor population. Indeed, we show that these mutations are rapidly selected for in cells upon inhibitor treatment; increasing up to 50-fold in only 3 days selection with a GI 50 concentration. Mutations conferring resistance to BCR-ABL1 inhibitors have also been shown to be present in both pre-and postinhibitor treated tumors (24, 44) . Likewise, the p.T790M gatekeeper mutation in EGFR has been detected pretreatment in non-small cell lung cancer, although this mutation is thought to have some oncogenic properties (45) (46) (47) . Our data significantly expand upon these previous studies in showing, for the first time, that both MPS1 and EGFR drug-resistant mutations are preexisting not only in a large number of cancer cell lines and tumors, but are also naturally occurring in healthy, normal lymphoblast and breast tissues. This result is contrary to preexisting MET amplifications (causing resistance to gefitinib), which is suggested to be cell-line specific (48) . This suggests that the origin of mutations causing acquired resistance may not be a result of high mutagenic rates in cancer cells as previously thought, but from naturally occurring mutations in normal tissues. Although we cannot rule out some low-level selective advantage for these MPS1 mutations, we believe that their constant low levels in cancer cell lines, as well as their emergence within weeks of expanding clonal populations, suggests that these residues are frequently and specifically mutated.
The knowledge that mutations conferring resistance to kinaseinhibitor therapy are preexisting in normal cells highlights the need to identify strategies to overcome drug-resistance early during drug development. Although the p.S611G mutation typically caused high resistance to all inhibitors tested, NMS-P715 was unaffected, highlighting the potential to synthesize compounds to overcome this common resistant mutation. Likewise, the p.I531M and p.Y568C mutations were not effective at causing resistance to SNG12 and CCT251455, respectively. However, of concern, we found that the p.C604W MPS1 mutation conferred resistance to all the inhibitors tested, due to the steric hindrance caused by the bulky Trp residue in the hinge-binding region. Nevertheless, based on the crystal structure of CCT251455 bound to MPS1, we were able to design two compounds that not only avoid this clash, but that more potently targeted the mutant compared with WT kinase. Because all the mutations identified in this study were preexisting in cancer cells, it would suggest that the development of acquired resistance is an inevitable outcome following inhibitor treatment with a single agent. However, because different inhibitors remain effective against distinct mutations, we would suggest that using a variety of MPS1 inhibitors, either in combination or via cyclical treatment, may be beneficial in combating the development of resistance. Alternatively, by monitoring the development of mutations in a relapsing tumor, it would be possible to then select the appropriate inhibitor to overcome the resistance as a second line treatment.
In conclusion, our data would agree with Diaz and colleagues (49) that resistance is a "fait accompli". However, we demonstrate that the drug-resistant mutations are actually preexisting in normal, as well as cancer cells, most likely being introduced during continued proliferation. This would explain why acquired resistance is so rapidly encountered in the clinic with targeted therapies and suggests it is imperative to identify and prepare strategies to address this issue early during drug discovery.
